Page 1

November 4 , 2021 Adaptimmune TRANSFORMING T CELL THERAPY Adaptimmune Reports Third Quarter Financial Results and Business Update - Strategic Collaboration Agreement with Genentech has started after expiration of HSR waiting periods ; Adaptimmune set to receive $ 150 million upfront payment - - SURPASS trial data at ESMO confirms potential of MAGE - A4 franchise across a range of tumors : overall response rate of 36 % and 86 % disease control rate with responses in five different solid tumors - - Initiated Phase 2 SURPASS - 2 trial investigating next - generation ADP - A2M4CD8 in patients with esophageal and EGJ cancers - - Will initiate Phase 2 SURPASS - 3 trial to investigate ADP - A2M4CD8 in ovarian cancer in 2022 - - Ceased enrollment in the SPEARHEAD - 2 trial , and will evaluate the use of checkpoint inhibitors in combination with ADP - A2M4CD8 - - Data presented at ILCA from the ADP - A2AFP Phase 1 trial ; screening will close in this trial - Allogeneic platform progress , including planning for IND submission in 2023 for first product targeting MAGE - A4 and opening a new allogeneic manufacturing facility in 2022 - - Clinical update and translational data from SPEARHEAD - 1 in patients with synovial sarcoma and MRCLS to be presented at CTOS - - Translational data from Phase 1 SURPASS trial to be presented at SITC - - Financial guidance confirmed : funded into early 2024 - - Conference call to be held today at 8:00 a.m. EDT ( 12:00 p.m. GMT ) - PHILADELPHIA and OXFORD , United Kingdom , Nov. 04 , 2021 ( GLOBE NEWSWIRE ) -- Adaptimmune Therapeutics plc ( Nasdaq : ADAP ) , a leader in cell therapy to treat cancer , today reported financial results for the third quarter ended September 30 , 2021 , and provided a business update . " We made excellent progress in Q3 . The SURPASS data presented at ESMO , the start of our first Phase 2 trial with ADP - A2M4CD8 next - gen SPEAR T - cells , and the announcement of our strategic collaboration with Genentech all support our 2-2-5-2 strategy , " said Adrian Rawcliffe , Adaptimmune's Chief Executive Officer . “ Looking ahead , the SPEARHEAD - 1 data that we will present at the CTOS meeting will support a BLA for afami - cel in 2022. Next year , we will initiate a Phase 2 trial with ADP - A2M4CD8 for patients with ovarian cancer and evaluate the combination of this next - generation therapy with checkpoint inhibitors . All these